Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 7/20 | 0.76 |
| ▸ | BCL9 | O00512 | 1/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.45 |
| ▸ | LSS | P48449 | 2/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23912633 | 0.90 | MGLL (0.61) | MGLLBCL9CTNNB1KCNH2GAA | |
| SCHEMBL1400533 | 0.87 | MGLL (1.00) | MGLLBCL9CTNNB1 | |
| SCHEMBL2773144 | 0.85 | MGLL (0.97) | MGLLBCL9CTNNB1FAAHTRPV1 | |
| SCHEMBL21634482 | 0.84 | MGLL (0.80) | MGLLBCL9CTNNB1 | |
| SCHEMBL16139295 | 0.84 | MGLL (1.00) | MGLLBCL9CTNNB1FAAHTRPV1 | |
| SCHEMBL26616595 | 0.82 | MGLL (0.66) | MGLLBCL9CTNNB1KCNH2GAA | |
| SCHEMBL14617269 | 0.81 | MGLL (0.84) | MGLLBCL9CTNNB1GAAFAAH | |
| SCHEMBL18291923 | 0.81 | MGLL (0.51) | MGLLKCNH2GAAFAAHLSS | |
| SCHEMBL9263126 | 0.81 | MGLL (0.92) | MGLLBCL9CTNNB1FAAHTRPV1 | |
| SCHEMBL21634484 | 0.81 | MGLL (0.86) | MGLLBCL9CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180154005-A1 | CONJUGATES COMPRISING AN GLP-1/GLUCAGON DUAL AGONIST, A LINKER AND HYALURONIC ACID | SANOFI (FR) | 2018-06-07 | — | — | US | disclosed |
| US-9133276-B2 | Prodrugs comprising an exendin linker conjugate | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2015-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180154005-A1 | CONJUGATES COMPRISING AN GLP-1/GLUCAGON DUAL AGONIST, A LINKER AND HYALURONIC ACID | GLP1R, GIPR, GCGR | MGLL 437/4885BCL9 3202/4885CTNNB1 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.